Global Gemtuzumab Ozogamicin Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Published on: 2024-01-04 | No of Pages : 400 | Industry : Pharma & Healthcare
Publisher : MRA | Format : PDF
Global Gemtuzumab Ozogamicin Drugs Market Report, History and Forecast 2018-2034, Breakdown Data by Manufacturers, Key Regions, Types and Application
Gemtuzumab ozogamicin is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010.
Gemtuzumab Ozogamicin Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gemtuzumab Ozogamicin Drugs market is projected to reach US$ 179.5 million in 2029, increasing from US$ 214.3 million in 2022, with the CAGR of -2.5% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
Gemtuzumab Ozogamicin is an antibody-drug conjugate used to treat certain types of acute myeloid leukemia (AML). Its efficacy in targeting CD33-expressing AML cells and inducing remission has driven market growth. The limited treatment options for CD33-positive AML contribute to its niche status. However, challenges include potential side effects and the need for careful patient selection. The market competition is relatively small, as Gemtuzumab Ozogamicin remains a targeted therapy for a specific AML subgroup. Despite challenges, the Gemtuzumab Ozogamicin market offers potential for growth as healthcare providers seek effective treatments for patients with CD33-positive AML. Continued research and clinical advancements can further drive market expansion.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gemtuzumab Ozogamicin Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
Pfizer
Segment by Type
5mg/Vial
4.5mg/Vial
Hospital
Pharmacy
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Gemtuzumab Ozogamicin Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Gemtuzumab Ozogamicin Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Gemtuzumab Ozogamicin Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Gemtuzumab Ozogamicin Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Gemtuzumab Ozogamicin Drugs introduction, etc. Gemtuzumab Ozogamicin Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Gemtuzumab Ozogamicin Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Gemtuzumab Ozogamicin Drugs report published by Mr Accuracy reports reveals that COVID-19 and Russia-Ukraine War impacted the market dually in 2022. Global Gemtuzumab Ozogamicin Drugs market is projected to reach US$ 179.5 million in 2029, increasing from US$ 214.3 million in 2022, with the CAGR of -2.5% during the period of 2024 to 2029. Demand from Hospital and Pharmacy are the major drivers for the industry.
Gemtuzumab Ozogamicin is an antibody-drug conjugate used to treat certain types of acute myeloid leukemia (AML). Its efficacy in targeting CD33-expressing AML cells and inducing remission has driven market growth. The limited treatment options for CD33-positive AML contribute to its niche status. However, challenges include potential side effects and the need for careful patient selection. The market competition is relatively small, as Gemtuzumab Ozogamicin remains a targeted therapy for a specific AML subgroup. Despite challenges, the Gemtuzumab Ozogamicin market offers potential for growth as healthcare providers seek effective treatments for patients with CD33-positive AML. Continued research and clinical advancements can further drive market expansion.
Report Scope
This report, based on historical analysis (2018-2022) and forecast calculation (2024-2034), aims to help readers to get a comprehensive understanding of global Gemtuzumab Ozogamicin Drugs market with multiple angles, which provides sufficient supports to readers’ strategy and decision making.
Manufacturers, Type, Application and Regions Listed in the Report
By Company
Pfizer
Segment by Type
5mg/Vial
4.5mg/Vial
Segment by Application
Hospital
Pharmacy
Segment by Region
North America
the United States
Canada
Europe
Germany
France
UK
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Each chapter of the report provides detailed information for readers to understand the Gemtuzumab Ozogamicin Drugs market further
Chapter 1Product Definition, Product Types, Volume and Revenue analysis of Each Type in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 2Manufacturer Competition Status, including Sales and Revenue comparison, Manufacturers’ commercial date of Gemtuzumab Ozogamicin Drugs, product type offered by each manufacturer, Mergers & Acquisitions activities, Expansion activities occurred in the Gemtuzumab Ozogamicin Drugs industry.
Chapter 3Historical (2018-2022) and forecast (2024-2034) volume and revenue analysis of Gemtuzumab Ozogamicin Drugs in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa.
Chapter 4Product Application, Volume and Revenue analysis of Each Application in North America, Europe, Asia-Pacific, Latin America, Middle East and Africa from 2018 to 2024.
Chapter 5 to 9Country Level analysis of North America, Europe, Asia-Pacific, Latin America, Middle East and Africa, including volume and revenue analysis.
Chapter 10Manufacturers’ Outline, covering company’s basic information like headquarter, contact information, major business, Gemtuzumab Ozogamicin Drugs introduction, etc. Gemtuzumab Ozogamicin Drugs Sales, Revenue, Price and Gross Margin of each company as well as Recent Development are also contained in this part.
Chapter 11Industry Chain, like raw materials, manufacturing cost, are covered. In addition, market opportunities and challenges are emphasized as well in the chapter.
Chapter 12Market Channel, Distributors and Customers are listed.
Chapter 13Mr Accuracy reports’s Conclusions of Gemtuzumab Ozogamicin Drugs market based on comprehensive survey.
Chapter 14Methodology and Data Sources adopted by Mr Accuracy reports.
Electronic and Semiconductor
Food and Beverages
Chemicals and Materials
Consumer Goods
Construction Manufacturing
Aerospace and Defence
Energy and Power
ICT Media
Banking and Finance
Automotive and Transportation
Machinery and Equipments
Pharmaceutical and Healthcare
Medical Devices